- Home
- ICG vs OPT Comparison
ICG vs OPT Comparison
Compare ICG & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- OPT
- Stock Information
- Founded
- ICG 2017
- OPT 1984
- Country
- ICG China
- OPT Australia
- Employees
- ICG N/A
- OPT N/A
- Industry
- ICG Semiconductors
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICG Technology
- OPT Health Care
- Exchange
- ICG Nasdaq
- OPT Nasdaq
- Market Cap
- ICG 559.6M
- OPT 574.0M
- IPO Year
- ICG 2023
- OPT 2020
- Fundamental
- Price
- ICG $4.33
- OPT $3.90
- Analyst Decision
- ICG Strong Buy
- OPT Strong Buy
- Analyst Count
- ICG 1
- OPT 1
- Target Price
- ICG $11.00
- OPT $12.00
- AVG Volume (30 Days)
- ICG 587.3K
- OPT 18.3K
- Earning Date
- ICG 02-26-2025
- OPT 02-26-2025
- Dividend Yield
- ICG N/A
- OPT N/A
- EPS Growth
- ICG N/A
- OPT N/A
- EPS
- ICG 0.11
- OPT N/A
- Revenue
- ICG $34,648,799.00
- OPT $261,859.00
- Revenue This Year
- ICG N/A
- OPT N/A
- Revenue Next Year
- ICG $74.94
- OPT $46,864.26
- P/E Ratio
- ICG $38.92
- OPT N/A
- Revenue Growth
- ICG 202.16
- OPT N/A
- 52 Week Low
- ICG $2.80
- OPT $1.79
- 52 Week High
- ICG $12.04
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- ICG 47.12
- OPT 56.41
- Support Level
- ICG $3.81
- OPT $3.59
- Resistance Level
- ICG $4.66
- OPT $3.90
- Average True Range (ATR)
- ICG 1.64
- OPT 0.24
- MACD
- ICG -0.11
- OPT 0.02
- Stochastic Oscillator
- ICG 16.56
- OPT 74.11
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.